Meyd-773

Tsukasa Aoi is a well-known figure in the Japanese entertainment industry, having debuted in the late 2000s. Over her career, she has appeared in numerous productions, variety shows, and films, becoming one of the more recognized names associated with the Meidi label during this period.

Please provide more information, and I'll do my best to help you develop a well-structured and informative paper about MEYD-773. MEYD-773

Triple‑negative breast cancer (TNBC) accounts for ~15‑20 % of all breast cancers and is characterized by an aggressive clinical course, early metastasis, and a paucity of targeted therapies (1). Genomic analyses have highlighted the phosphatidylinositol‑3‑kinase (PI3K)/AKT/mTOR axis as a central driver of proliferation, survival, and chemoresistance in TNBC (2,3). While several pan‑class I PI3K inhibitors have entered clinical testing, dose‑limiting toxicities—particularly hyperglycemia, rash, and immune suppression—have limited their therapeutic window (4). Consequently, there is a critical need for next‑generation PI3K inhibitors with improved selectivity, oral bioavailability, and tumor‑specific activity. Tsukasa Aoi is a well-known figure in the